default author photo

Shanghua Jing

Hebei Medical University - Fourth Hospital

No.12Jian-kangSt

Shijiazhuang

China

SCHOLARLY PAPERS

2

DOWNLOADS

250

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

JUPITOR-02: Randomized, Double-Blind, Phase 3 Study of Toripalimab or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Number of pages: 35 Posted: 16 Apr 2021
Prince of Wales Hospital - State Key Laboratory of Oncology in South China, Prince of Wales Hospital - State Key Laboratory of Oncology in South China, Guangzhou Medical University - Department of Radiation Oncology, Fudan University - Department of Radiation Oncology, Huazhong University of Science and Technology - Cancer Center, Guangdong Medical University - Affiliated Hospital, Jiangxi Cancer Hospital - Department of Head and neck radiotherapy, Central South University - Hunan Cancer Hospital, Fujian Provincial Cancer Hospital, Fujian Medical University - Fujian Provincial Hospital, People’s Hospital of Guangxi Zhuang Autonomous Region, Sichuan University - West China Hospital, Central South University - Second Xiangya Hospital, Taichung Veterans General Hospital, Shantou University Medical College - Cancer Hospital, Jiangsu Cancer Hospital, Chang Gung University - Chang Gung Memorial Hospital, National Cancer Centre Singapore, Southern Medical University - Department of Oncology, Chinese Academy of Medical Sciences - Peking Union Medical College, Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Sun Yat-sen University (SYSU) - Fifth Affiliated Hospital, Huazhong University of Science and Technology - Department of Oncology, Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital, Fujian Medical University - Union Hospital, Hebei Medical University - Fourth Hospital, Hainan Medical University - Hainan General Hospital, Liuzhou Worker’s Hospital, China Medical University - College of Medicine, National Chiao Tung University - Institute of Clinical Medicine, National Cheng Kung University - Department of Internal Medicine, Tan Tock Seng Hospital, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, TopAlliance Biosciences and Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China
Downloads 179 (422,345)

Abstract:

Loading...

Nasopharyngeal Carcinoma, anti-PD-1 antibody, Toripalimab

2.

Efficacy and Safety of KL-A167 in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Single-Arm, Phase 2 Study

Number of pages: 33 Posted: 22 Mar 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Guangdong Pharmaceutical University - Department of Medical Oncology, Sichuan University - Collaborative Innovation Center for Biotherapy, Guangxi Medical University - Department of Respiratory Oncology, Jiangxi Cancer Hospital - Department of Head and neck radiotherapy, Fujian Medical University - Department of Radiation Oncology, Fujian Medical University - Department of Radiation Oncology, Yue Bei People's Hospital - Department of Oncology Radiotherapy, Zhejiang University - Department of Medical Oncology, Nantong Tumor Hospital - Department of Oncology Radiotherapy, Chongqing Medical University - First Affiliated Hospital, The People's Hospital of Guangxi Zhuang Autonomous Region - Department of Head and neck surgery, Guangzhou University of Chinese Medicine - Department of Oncology, Fujian Medical University - Department of Radiation Oncology, Zhengzhou University - Henan Cancer Hospital, Liuzhou Worker’s Hospital - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Anhui Provincial Cancer Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Guangdong Medical University - Department of Oncology, Fudan University - Internal Medicine Oncology, Government of the People's Republic of China - Department of Oncology, Nanchang University - Department of Medical Oncology, Huazhong University of Science and Technology - Department of Oncology, Hebei Medical University - Fourth Hospital, Harbin Medical University - Department of Medical Breast oncology, Nanjing Medical University - Department of Oncology, Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital, Fujian Medical University - Department of Radiation Oncology, Guizhou Medical University (Guiyang Medical University) - Department of Head and Neck oncology, Haikou People’s Hospital - Department of Medical Oncology, Linyi Cancer Hospital - Department of Medical Oncology, Tianjin Medical University - Department of Oncology Radiotherapy, Jilin University (JLU) - Cancer Center, Huazhong University of Science and Technology - Cancer Center, Wenzhou Medical University - Department of Medical Oncology, Yunnan Cancer Hospital, Central South University - Department of Oncology, Central South University - Department of Oncology, Shandong University - Department of Head and Neck neoplasm, Dalian University - Department of Oncology, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Downloads 71 (867,774)

Abstract:

Loading...

KL-A167, nasopharyngeal carcinoma, efficacy, safety, PD-L1, biomarker